



SPAFID  
CONNECT

Informazione Regolamentata n. 20106-38-2022	Data/Ora Ricezione 12 Maggio 2022 10:27:23	Euronext Star Milan
---------------------------------------------------	--------------------------------------------------	---------------------

Societa' : PHARMANUTRA  
Identificativo : 162064  
Informazione  
Regolamentata  
Nome utilizzatore : PHARMANUTRAN04 - Roberto Lacorte  
Tipologia : REGEM  
Data/Ora Ricezione : 12 Maggio 2022 10:27:23  
Data/Ora Inizio : 12 Maggio 2022 10:27:24  
Diffusione presunta  
Oggetto : PR - PHN Interim financial report as of 31  
March 2022

*Testo del comunicato*

Vedi allegato.

## PHARMANUTRA S.P.A.: INTERIM FINANCIAL REPORT AS OF 31 MARCH 2022 NOW AVAILABLE

Pisa, May 12<sup>th</sup> 2022 - PharmaNutra S.p.A. (MTA; Ticker PHN) announces that the Interim Financial Report as of 31<sup>st</sup> March 2022, as approved by the Board of Directors of the Company on May 9<sup>th</sup> 2022, is available at the Company's registered office, on PharmaNutra S.p.A. website ([www.pharmanutra.it](http://www.pharmanutra.it), section *Investor Relations*) and on the authorized storage mechanism "eMarket Storage" available on the website ([www.emarketstorage.it](http://www.emarketstorage.it)).

### PharmaNutra S.p.A.

*Established and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique nutritional supplements and innovative medical devices, taking care of the entire production process, from proprietary raw materials to the finished product. The effectiveness of the products is demonstrated by a wealth of scientific evidence, including 135 publications with over 7,000 subjects involved. The Group distributes and sells in Italy and abroad. In Italy, the sales activity is carried out through a network of over 150 Scientific Sales Representatives at the service of the medical class, also dedicated to the exclusive marketing of PharmaNutra products to pharmacies throughout the country. Sales abroad are guaranteed in over 60 countries through 41 partners selected among the leading pharmaceutical companies. PharmaNutra is a leader in the production of iron-based nutritional supplements under the brand name SiderAL®, for which it boasts key patents for the Sucrosomial® Technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, based on the integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence.*

[PharmaNutra.it](http://PharmaNutra.it)

For further details:

### PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Internal Press Office

[press@calabughi.com](mailto:press@calabughi.com)

### Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

Cristina Tronconi

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

Fine Comunicato n.20106-38

Numero di Pagine: 3